[Safety and efficacy assessments using human iPS cell-derived cardiomyocytes]

Area of Science:

• Biotechnology
• Toxicology
• Stem Cell Research

Background:

• Drug development faces challenges with delays and losses, necessitating improved non-clinical testing.
• There is a global trend towards alternatives to animal testing in drug development.
• New Approach Methodologies (NAMs) are crucial for enhancing drug safety and efficacy evaluations.

Purpose of the Study:

• To explore the application of human inducible pluripotent stem cell (hiPSC) technology in non-clinical drug evaluation.
• To highlight the potential of hiPSC-derived models for assessing drug-induced cardiotoxicity.
• To discuss future perspectives on personalized non-clinical testing using hiPSC technology.

Main Methods:

• Utilizing human inducible pluripotent stem cell (hiPSC) technology for drug safety assessment.
• Employing hiPSC-derived cardiomyocytes (hiPSC-CMs) to evaluate cardiotoxicity.
• Developing engineered heart tissues from hiPSCs for advanced drug testing.
• Exploring in silico modeling and simulation as complementary NAMs.

Main Results:

• hiPSC-CMs are effective tools for assessing drug-induced cardiotoxicity, including arrhythmia and contractile dysfunction.
• hiPSC-CMs are being integrated into regulatory drug review processes.
• Advancements in hiPSC technology enable the generation of mature cells and engineered tissues for comprehensive evaluation.
• hiPSC technology holds promise for personalized non-clinical testing, considering specific patient populations.

Conclusions:

• hiPSC technology represents a significant advancement in non-clinical drug evaluation, offering alternatives to animal testing.
• The use of hiPSC-derived models enhances the assessment of drug safety and efficacy.
• Future development of hiPSC technology can lead to personalized non-clinical testing, improving drug development outcomes.